senhwabiosciences.com

Welcome to SENHWA BIOSCIENCES, INC. | Senhwa Biosciences (Senhwa) is a new drug development company registered in the Taiwan with operations in Taiwan and USA.

Language: English Traditional Chinese. Senhwa Biosciences identifies and develops innovative therapies that will fundamentally change the way patients are treated. Senhwa is developing small molecule oncology drugs targeting Pol I and CK2. Senhwa Biosciences Receives Permission for Korean Phase 1/2 Trial of CX-4945 in Combination with Gemcitabine and Cisplatin. Inhibitor of RNA Polymerase I Shows Promise as Potential Treatment for Acute Myeloid Leukemia and Multiple Myeloma.

http://www.senhwabiosciences.com/

OVERVIEW OF senhwabiosciences.com

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

9

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR SENHWABIOSCIENCES.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

August

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Thursday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 3.5 out of 5 with 10 reviews

5 star

3

4 star

3

3 star

2

2 star

0

1 star

2

Hey there! Start your review of senhwabiosciences.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

2.1 seconds

CONTACTS AT SENHWABIOSCIENCES.COM

edirect corp.

mailer my

13F., No.102, G●●●●●●●●●●●●●●● Da-an District

Ta●●ei , Taiwan, 106

TW

886.●●●●8077

886.●●●●8076

po●●●●●●@senhwabio.com

View this contact

edirect corp.

mailer my

13F., No.102, G●●●●●●●●●●●●●●● Da-an District

Ta●●ei , Taiwan, 106

TW

886.●●●●8077

886.●●●●8076

po●●●●●●@senhwabio.com

View this contact

edirect corp.

mailer my

13F., No.102, G●●●●●●●●●●●●●●● Da-an District

Ta●●ei , Taiwan, 106

TW

886.●●●●8077

po●●●●●●@senhwabio.com

View this contact

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

DOMAIN REGISTRATION INFORMATION

REGISTERED: 2013 July 15
UPDATED: 2014 June 30
EXPIRATION: EXPIRED REGISTER THIS DOMAIN

BUY YOUR DOMAIN

DOMAIN AGE

10

YEARS
10

MONTHS
16

DAYS

NAME SERVERS

1: dns.twmail.org
2: dns2.twmail.org

REGISTRAR

WEB COMMERCE COMMUNICATIONS LIMITED DBA WEBNIC.CC

WHOIS : whois.webnic.cc

REFERRED : http://www.webnic.cc

CONTENT

PAGES IN
THIS WEBSITE

9

SSL

EXTERNAL LINKS

3

SITE IP

210.242.73.200

LOAD TIME

2.094 sec

SCORE

6.2

PAGE TITLE

Welcome to SENHWA BIOSCIENCES, INC. | Senhwa Biosciences (Senhwa) is a new drug development company registered in the Taiwan with operations in Taiwan and USA. | senhwabiosciences.com Reviews

<META> DESCRIPTION

Language: English Traditional Chinese. Senhwa Biosciences identifies and develops innovative therapies that will fundamentally change the way patients are treated. Senhwa is developing small molecule oncology drugs targeting Pol I and CK2. Senhwa Biosciences Receives Permission for Korean Phase 1/2 Trial of CX-4945 in Combination with Gemcitabine and Cisplatin. Inhibitor of RNA Polymerase I Shows Promise as Potential Treatment for Acute Myeloid Leukemia and Multiple Myeloma.

<META> KEYWORDS

1 about us

2 company profile

3 management team

4 clinical consultants

5 pipeline

6 clinical trial

7 newsroom

8 us office

9 taiwan office

10 senhwa biosciences

CONTENT

Page content here

KEYWORDS ON PAGE

SERVER

Apache

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

Welcome to SENHWA BIOSCIENCES, INC. | Senhwa Biosciences (Senhwa) is a new drug development company registered in the Taiwan with operations in Taiwan and USA. | senhwabiosciences.com Reviews

https://senhwabiosciences.com

Language: English Traditional Chinese. Senhwa Biosciences identifies and develops innovative therapies that will fundamentally change the way patients are treated. Senhwa is developing small molecule oncology drugs targeting Pol I and CK2. Senhwa Biosciences Receives Permission for Korean Phase 1/2 Trial of CX-4945 in Combination with Gemcitabine and Cisplatin. Inhibitor of RNA Polymerase I Shows Promise as Potential Treatment for Acute Myeloid Leukemia and Multiple Myeloma.

INTERNAL PAGES

senhwabiosciences.com

1

Senhwa Biosciences Receives Permission for Korean Phase 1/2 Trial of CX-4945 in Combination with Gemcitabine and Cisplatin | Welcome to SENHWA BIOSCIENCES, INC.

http://www.senhwabiosciences.com/senhwa-biosciences-receives-permission-for-korean-phase-12-trial-of-cx-4945-in-combination-with-gemcitabine-and-cisplatin

Language: English Traditional Chinese. Senhwa Biosciences Receives Permission for Korean Phase 1/2 Trial of CX-4945 in Combination with Gemcitabine and Cisplatin. Senhwa Biosciences Receives Permission for Korean Phase 1/2 Trial of CX-4945 in Combination with Gemcitabine and Cisplatin. About CX-4945 and DNA repair. Senhwa plans Taiwan exchange uplisting, US ovarian cancer clinical trial with DNA repair inhibitor. Language: English Traditional Chinese.

2

Senhwa Biosciences Initiates Phase 1/2 Trial of CX-4945 in Combination with Gemcitabine and Cisplatin | Welcome to SENHWA BIOSCIENCES, INC.

http://www.senhwabiosciences.com/senhwa-biosciences-initiates-phase-12-trial-of-cx-4945-in-combination-with-gemcitabine-and-cisplatin

Language: English Traditional Chinese. Senhwa Biosciences Initiates Phase 1/2 Trial of CX-4945 in Combination with Gemcitabine and Cisplatin. Senhwa Biosciences Initiates Phase 1/2 Trial of CX-4945 in Combination with Gemcitabine and Cisplatin. Senhwa Biosciences Initiates Phase 1,2 Trial of CX-4945 in Combination with Gemcitabine and Cisplatin. Proof-of-Concept Trial Targets DNA Repair in Bile Duct Cancers. New Taipei City and San Diego, CA, 17th June 2014. Positive results in this orphan indication may...

3

Inhibitor of RNA Polymerase I Shows Promise as Potential Treatment for Acute Myeloid Leukemia and Multiple Myeloma | Welcome to SENHWA BIOSCIENCES, INC.

http://www.senhwabiosciences.com/inhibitor-of-rna-polymerase-i-shows-promise-as-potential-treatment-for-acute-myeloid-leukemia-and-multiple-myeloma-2-2

Language: English Traditional Chinese. Inhibitor of RNA Polymerase I Shows Promise as Potential Treatment for Acute Myeloid Leukemia and Multiple Myeloma. Inhibitor of RNA Polymerase I Shows Promise as Potential Treatment for Acute Myeloid Leukemia and Multiple Myeloma. Senhwa plans Taiwan exchange uplisting, US ovarian cancer clinical trial with DNA repair inhibitor. Health Canada Approves Clinical Trial Application (CTA) for Phase I/II Clinical Trial of CX-5461 in Solid Tumors and Breast Cancers.

4

Platform | Welcome to SENHWA BIOSCIENCES, INC.

http://www.senhwabiosciences.com/pipeline-2

Language: English Traditional Chinese. NOVEL SOLUTION FOR DNA REPAIR INHIBITION. NOVEL SOLUTION FOR DNA REPAIR INHIBITION. Language: English Traditional Chinese. US Office Address: 10509 Vista Sorrento Parkway, Suite 201, San Diego, CA 92121 Tel: 1-858- 552-6808 Fax: 1-858-552-6811. Taiwan Office Address: 9F., No.205-1, Sec. 3,Peihsin Rd, Hsintien District., New Taipei City 23143, Taiwan (R.O.C.) Tel: 886-2-8913-1956 Fax: 886-2-8913-1955.

5

Clinical Consultants | Welcome to SENHWA BIOSCIENCES, INC.

http://www.senhwabiosciences.com/clinical-consultants

Language: English Traditional Chinese. NOVEL SOLUTION FOR DNA REPAIR INHIBITION. NOVEL SOLUTION FOR DNA REPAIR INHIBITION. Daniel D. Von Hoff, M.D., F.A.C.P. Clinical Advisor. Keith Chan Clinical Advisor. Currently the Physician-in-Chief and Distinguished Professor for Translational Research Division at TGen. He holds an appointment as Professor of Medicine, Mayo Clinic, Scottsdale, AZ. Dr Von Hoff has been involved in developing many new anticancer drugs, and has published extensively. His experience in...

UPGRADE TO PREMIUM TO VIEW 4 MORE

TOTAL PAGES IN THIS WEBSITE

9

LINKS TO THIS WEBSITE

sanderling.com

Sanderling Ventures - Building new biomedical companies

http://www.sanderling.com/index.php

Dedicated to biomedical financing and active management. Dedicated to early-stage biomedical financing and active management. Pulsar Vascular Intra Aneursym Implant. Founded in 1979, Sanderling is among the oldest investment firms dedicated to building new biomedical companies. We demonstrate that significant companies are best built in close working partnerships with entrepreneurs. How We Can Help. August 12, 2016. ViaCyte to Present at Rejuvenation Biology 2016. August 4, 2016. July 13, 2016.

UPGRADE TO PREMIUM TO VIEW 2 MORE

TOTAL LINKS TO THIS WEBSITE

3

OTHER SITES

senhuwpc.com

-浙江森虎复合材料科技有限公司

地址浙江省富阳市鹿山街道裕阳路1号电话 0571-63473866 传真 0571-63473866. 联系人陈先生手机 13336168230 网址 www.senhuwpc.com.

senhuxi.net

迁安市时光电子商务有限公司生活分类信息网

迁安市时光电子商务有限公司新媒体、新服务、新生活地址迁安市大三元街12号. 电话/微信 18132541678 QQ 1801297111. 经营宗旨- 公司本着以诚为本的经营宗旨，以人为本的管理哲学，以质量和服务取胜。美乐士MIROX系列润滑油采用了进口基础油和雪佛龙高性能添加剂，美国专利技术 MIPP 和世界先进润滑油配方 MiroSyn* ，并采用独特的全温层润滑配方所研制而成的功能性润滑油 Funtional Motoroil ，其技术指标与性能更优于传统润滑油，本产品适用于各种先进引擎系统，包括欧、美、日、德等系列品牌车，以及其他进口、国产车使用。被业内称为未来的润滑油 Motor Oil of Furure。天津新好油脂有限公司本着环保从我们开始的经营理念，引进了高品质，低价位的美乐士润滑油服务于大陆市场。亚健康状态既是疾病先导，也是早衰的先兆，处于亚健康状态的人若处理得当可以向健康转化若得不到及时调治，则容易向各种疾病转化，如向高血压、冠心病、糖尿病、脑血管疾病、癌症、心理障碍等疾病转化亚健康状态部分人群进一步恶化就有可能出现过劳死或无病猝死。

senhuxihb.com

苏州森呼吸环保科技有限公司

senhuyuanyi.com

南昌花卉|江西花卉|南昌花卉市场|江西花卉市场|立体绿化-南昌森湖园艺公司

senhwabio.com

Welcome to SENHWA BIOSCIENCES, INC. | Senhwa Biosciences (Senhwa) is a new drug development company registered in the Taiwan with operations in Taiwan and USA.

Language: English Traditional Chinese. Senhwa Biosciences identifies and develops innovative therapies that will fundamentally change the way patients are treated. Senhwa is developing small molecule oncology drugs targeting Pol I and CK2. Senhwa Biosciences Receives Permission for Korean Phase 1/2 Trial of CX-4945 in Combination with Gemcitabine and Cisplatin. Inhibitor of RNA Polymerase I Shows Promise as Potential Treatment for Acute Myeloid Leukemia and Multiple Myeloma.

senhwabiosciences.com

Welcome to SENHWA BIOSCIENCES, INC. | Senhwa Biosciences (Senhwa) is a new drug development company registered in the Taiwan with operations in Taiwan and USA.

Language: English Traditional Chinese. Senhwa Biosciences identifies and develops innovative therapies that will fundamentally change the way patients are treated. Senhwa is developing small molecule oncology drugs targeting Pol I and CK2. Senhwa Biosciences Receives Permission for Korean Phase 1/2 Trial of CX-4945 in Combination with Gemcitabine and Cisplatin. Inhibitor of RNA Polymerase I Shows Promise as Potential Treatment for Acute Myeloid Leukemia and Multiple Myeloma.

senhy-group.com

深海有限公司

86 21 6184 3588. 86 1893 179 9905.

senhy.com

Sen Masine | Christmas Decoration manufactory supplier

CALL 0755 - 28542527. 3D Pop up Card. Sen Masine Christmas arts CO., LTD. is a professional Christmas decoration, Christmas ball, Christmas pick, Christmas Wreath, Christmas Garland and Chrismtas tree factory. With 20 years manufacturing experience in this field; and we are flexible for any customized products since we have our own mol. Happy new year of sheep! Phone 0755 - 28542527. FAX 0755 - 28542133. 40cm Colorful Christmas ball wreath. 21M Pine needle Christmas tree with light. Subscribe to our news.

senhyouren.com

襖（ふすま）壁紙クロス障子　張替/千表連（千葉県表具経師内装組合連合会）

襖ふすま壁紙クロス障子張替/千表連千葉県表具経師内装組合連合会. 第46回表美展千葉県立美術館の模様をユーチューブ動画サイトにてアップしました https:/ www.youtube.com/watch? V=uBlJfxgLc c&feature=youtu.be 第44回表美展開催5/8 12 ユーチューブ動画にてアップしました https:/ www.youtube.com/watch?

senhz.com

SENHZ graphic design services, graphic design, flash motion, print and web desing layout

seni--seviiyorum.skyrock.com

seni--seviiyorum's blog - SENI--SEViiYORUM - Skyrock.com

05/07/2008 at 10:27 AM. 15/05/2009 at 9:50 AM. Subscribe to my blog! Her özledigimde kalbime bir yildiz cizdim -. Ne kadar özledigimi bilmek istermisin? Don't forget that insults, racism, etc. are forbidden by Skyrock's 'General Terms of Use' and that you can be identified by your IP address (66.160.134.3) if someone makes a complaint. Please enter the sequence of characters in the field below. Posted on Sunday, 19 October 2008 at 6:03 AM. Edited on Monday, 27 October 2008 at 12:37 PM. 2 - ( Aşk.